FibroGen, Inc. — FY 2018 Form 10-K
Entity note: The supplied filing is FibroGen, Inc.’s Form 10-K, not a filing for Kyntra Bio, Inc. It covers the fiscal year ended December 31, 2018, and was filed February 27, 2019. Fourth-quarter figures are unaudited.
Business context and reporting period
FibroGen is a clinical-stage biopharmaceutical company developing roxadustat for anemia and pamrevlumab for fibrotic disease and cancer. Roxadustat received China approval in December 2018 for CKD-related anemia in dialysis patients; U.S. and European applications were in preparation with partners AstraZeneca and Astellas. The company had not yet generated revenue from commercial sales of an approved drug.
Financial performance and liquidity
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Revenue | $213.0 million | $131.0 million |
| Operating expenses | $299.7 million | $248.3 million |
| Operating loss | $86.7 million | $117.3 million |
| Net loss | $86.4 million; $1.03 per share | $120.9 million; $1.66 per share |
| Operating cash flow | $(76.1) million | $(66.5) million |
- Revenue rose 63%, principally reflecting $64.8 million of roxadustat API delivered to Astellas for Japan commercial-scale validation, plus collaboration milestones and development revenue. Collaboration partners accounted for essentially all revenue.
- R&D expense increased 20% to $235.8 million; G&A increased 23% to $63.8 million. Management cited higher pamrevlumab manufacturing, compensation, stock-based compensation and facility costs, partly offset by lower clinical-trial costs.
- Annual operating and net loss margins were approximately 40.7% and 40.6%, respectively. In Q4, revenue was $108.1 million, net income was $21.0 million, and diluted EPS was $0.23, versus a $33.9 million net loss in Q4 2017. The quarter’s revenue included the API deliveries and milestone recognition; it is not a clear indicator of recurring product sales.
- At year-end, cash and cash equivalents were $89.3 million, short-term investments $532.1 million, and long-term investments $55.8 million. Accounts receivable was $63.7 million; working capital was $601.0 million. Management said available resources, including receivables and expected collaboration revenue, were expected to fund operations for at least 12 months.
- Cash and cash equivalents decreased $584.4 million during 2018, largely because funds were moved into investments: investing cash outflow was $522.1 million, while operating cash outflow was $76.1 million. The filing reports $98.1 million of lease-financing obligations and $16.8 million of product-development obligations; no material legal proceedings were reported.
Material changes versus the prior comparable period
- Revenue increased from $131.0 million to $213.0 million, while net loss narrowed from $120.9 million to $86.4 million. Annual R&D and G&A spending both increased.
- FY 2018 included $64.8 million in API revenue tied to Japan launch-validation activity and recognition of collaboration milestones. These items contributed to an unusually strong fourth quarter.
- FibroGen adopted the new revenue standard retrospectively; prior-year revenue and related balances were recast. Reported FY 2017 revenue is therefore presented on the recast basis.
Outlook, commentary, risks and unusual items
- Management anticipated U.S. roxadustat NDA submission in Q3 2019, following pooled safety analyses expected in Q2; Astellas was expected to submit an EU application shortly thereafter. A Japan dialysis-CKD approval decision was expected in H2 2019.
- Management planned a China launch for dialysis patients in Q3 2019. Adding non-dialysis patients to the China label depended on regulatory site inspections. China approval also carries a required 2,000-patient post-approval safety study.
- Roxadustat’s Phase 3 trials met their reported primary efficacy endpoints, but pooled cardiovascular safety analyses—including MACE—were not yet complete. Safety, regulatory review, reimbursement, hospital listing, tendering and market uptake remain significant uncertainties.
- Pamrevlumab Phase 3 trials in IPF and locally advanced pancreatic cancer were planned to begin in Q2 2019; its DMD program remained in Phase 2. Roxadustat was also in Phase 3 development for MDS in the U.S./Europe and Phase 2/3 development in China.
- FibroGen warned that it expected continued losses and increased development and commercialization spending. Its business was highly dependent on roxadustat and on AstraZeneca and Astellas; either partner may terminate agreements under specified conditions, including for convenience.
- Other notable risks include potential roxadustat safety or drug-interaction findings (including with statins), competition from ESAs and other HIF-PH inhibitors, reliance on external manufacturers, patent challenges, and China-specific regulatory and market-access risks. The company reported no cash dividends planned for the foreseeable future.
Important facts for investors to verify
- Whether the pooled MACE/MACE+ safety analyses supported U.S. and EU filings, and whether regulators requested additional trials or imposed meaningful label restrictions.
- Actual timing and scope of U.S., EU, Japan and China regulatory decisions, including China non-dialysis inspections and post-approval safety requirements.
- Whether China launch, reimbursement-list inclusion, hospital listing, tendering and manufacturing qualification produced meaningful sales and profit-sharing revenue.
- How much future revenue depends on milestone accounting and one-time API validation deliveries, and whether the Japan API transaction price is subject to later adjustment.
- Cash burn, investment liquidity, receivable collection, lease obligations and collaboration funding against the stated 12-month runway; confirm that recurring operating needs remain adequately funded.